Review
Modern cancer therapy relies primarily on passive or active targeting approaches [1] . Passive targeting is based on the accumulation of therapeutics via the enhanced permeability and retention effect [2] [3] [4] 11] while active targeting [5, 6] uses specific ligands attached to the surface of pharmaceutical carriers to recognize and bind pathological cells. Increased secondary toxicity combined with a lower therapeutic index for both approaches are often the result of systemic circulation of the pharmaceutical agents. Although other complementary approaches are being investigated to enhance targeting efficacy, such as increasing circulation time, the amount of therapeutics being delivered at the target site compared with the administered dose still remains relatively low [7, 8] .
In recent years, various targeted delivery vehicles for advanced drug delivery have been designed and evaluated in animal models studies as well as in clinical trials [9] . Cytostatic drugs covalently attached to water-soluble polymers, polymeric nanoparticles, stabilized solid amorphous hydrophobic drug nanoparticles, polymeric nanoparticles, micelles loaded with hydrophobic drugs and liposomes loaded with both hydrophobic and hydrophilic drugs, are just some examples of such delivery vehicles. Doxil, a liposomal formulation of the cytostatic agent doxorubicin (DOX) is one example of the first systems that have entered the market. Although encouraging results with such targeted nanomedicines have been obtained, the extent of their deposition and accumulation in the tumor tissue still have to be improved considerably through better targeting strategies.
Furthermore, for several types of solid tumors, the therapeutic effect is often further reduced when the relatively small portion of the drug reaching the vicinity of the required region cannot diffuse deeper in the tumor due to a lack of sufficient flow caused by the tumor interstitial fluid pressure (TIFP) [10] . This is largely the result of an inadequate lymphatic system that limits drainage of excess fluid. In addition, oxygen concentrations in human tumors can become highly heterogeneous with approximately <0.7% O 2 (<5 mmHg partial pressure of oxygen) in difficult treatable hypoxic regions [12] . Hypoxic environments in solid tumors result from oxygen consumption by rapid proliferation of tumor cells. Such lack of oxygen in these regions leads to a negative impact on treatments based on radiotherapy while chemotherapy does not generally affect hypoxic cells that are generally beyond the diffusion limit of larger drug molecules or therapeutic agents while being distant from the blood vessels [13] [14] [15] [16] . Unfortunately, it appears that modern cancer therapies still fail to provide all the fundamental capabilities necessary to more efficiently target these hypoxic regions within solid tumors.
As a result of all previous efforts and results obtained in this field, it becomes clear that three fundamental complementary capabilities should be considered for existing and future therapeutic agents to optimize the efficacy of the treatment for specific types of cancer. One is the capability to reach the region to be treated using the most direct route with the help of navigable
Magnetic therapeutic delivery using navigable agents
For treating cancer in particular, therapeutic agents have evolved in complexity in an effort to enhance targeting efficacy. So far, efforts towards the synthesis alone of new therapeutics have attracted most attention. However, present cancer treatments frequently fail because of severe side effects related to the fact that the drug accumulates in insufficient concentration at the tumor site, while being distributed over healthy tissues and organs. More recently, advanced engineering principles have been considered for the development of platforms and drug-loaded vehicles to deliver payloads to the area to be treated by navigating them using the most direct route in order to improve tumor killing effects while minimizing toxic side effects caused by drug activity in nontargeted regions. If the introduction of engineering and principles of robotics to provide complementary techniques in targeted cancer therapy prove to be beneficial, it could influence future delivery methods and the synthesis of therapeutic carriers.
future science group agents and thus, avoiding or at least minimizing systemic circulation. The second would be the presence of a propelling force embedded or induced on the navigable agents to cope with the TIFP, especially for larger molecules, instead of relying on diffusion alone for moving towards the required regions inside solid tumors. Finally, the capability of detecting oxygen gradient and influencing accordingly the displacement of the therapeutic agents towards the hypoxic regions should be provided to achieve optimal treatment outcomes in specific tumoral environments.
To implement such complementary capabilities, it is obvious that among other requirements, a directional force must first be provided to influence the displacement of the therapeutic agents. As such, magnetism, which has been investigated in recent years, is obviously a promising avenue and a good starting point to assess the possibility of inducing the required directional force necessary for implementing navigable therapeutic vectors.
Fundamental requirements to optimize magnetically guided drug delivery
The use of magnetism to influence the movement of magnetic therapeutic agents has many advantages and has attracted significant attention in the field of drug delivery [17] . However, to improve the efficacy of magnetic targeting further, a fundamental understanding of the requirements to maximize the directional force on the magnetic agents (F magnetic ), in order to optimize drug delivery, is mandatory
where V ferro is the volume of magnetic material,
corresponds to the magnetization of the magnetic material and the rest of the term represents the magnetic gradient. The three fundamental requirements to maximize the induced directional force on a magnetic therapeutic agent are:
n To embed the maximum volume of magnetic material;
n Increase the magnetic field strength;
n Increase the magnetic gradient.
The magnetic nanoparticles (MNP) embedded in magnetic therapeutic agents are made of soft magnetic materials and are typically categorized as ferromagnetic or superparamagnetic. To increase the induced force on a MNP from a magnetic source, the magnetization M of the MNP must be maximized and as such, the saturation magnetization of the MNP, namely the maximum value that can be achieved must be considered while selecting an appropriate magnetic material. However, a sufficiently high-magnetic field strength (MFS) with the use of a sufficiently high-magnetic field (H in FiguRe 1 ) must also be provided to exploit the high-saturation magnetization level of such MNP since such magnetization will increase with an increase of the MFS until it reaches a plateau as depicted in FiguRe 1 . Presently, the highest saturation magnetization = 1.95 × 10 6 A/m can be achieved by immersing a soft magnetic core made of ironcobalt alloy containing 35% cobalt in a magnetic flux density (field B) ≥ 2.43 T. Compared with hard (permanent) Neodymium (Nd 2 Fe 14 B) magnet, for instance, with a typical saturation magnetization expressed as remanence = 1.3 T, the use of soft magnetic materials is certainly advantageous when smaller volumes of magnetic materials are required for the synthesis of navigable therapeutic agents designed for transiting through narrower blood vessels.
The magnetic gradient in equation 1 corresponds to a variation of the MFS along a given distance and it is used to move the magnetic agents in the direction of the highest magnetic strength. In equation 1, one can conclude that to decrease further the volume of the magnetic material, in order to implement smaller agents capable of operating in thinner vessels or constrained spaces, while providing room for the therapeutic payload, not only must the magnetic gradient be increased to a maximum possible value but it must also be directionally controlled in all directions in order to achieve effective navigation.
Magnetic therapeutic carriers
Although nanoparticles have been considered for drug delivery [18, 19] , MNP [20] , including superparamagnetic iron oxide nanoparticle [21] in clinical use for disease detection by MRI, were also considered as target drug delivery vectors with detection, the latter being referred to as theranostic agents. Although the
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future science group saturation magnetization of iron oxide is not optimal compared with other materials, it is still acceptable with the advantage of being widely used clinically. However, the use of individual MNP or superparamagnetic iron oxide nanoparticles results in a very low volume of magnetic material, which must be compensated by higher gradient fields as shown in equation 1. However, due to the limit in the gradient field that can be generated, especially when targeting deeper in the tissues, the resulting magnetic force applied on such therapeutic vectors becomes inadequate to achieve proper endovascular navigation towards the target site.
One obvious approach to induce more directional forces is to increase the effective volume of magnetic material (V ferro in equation 1). This can typically be done using aggregates of MNP or by encapsulating many MNP in a single matrix. For the former approach, when immersed in a magnetic field, MNP not only become more magnetized but they become attracted to each other due to dipole-dipole interactions, forming relatively large aggregates. Although such aggregates increase the effective volume of magnetic material leading to an increase of the magnetic force being induced, each aggregate can also lead to an unplanned pre-embolization when transiting towards narrower vessels before reaching the planned target site. Since the size of such aggregates is hard to control, unpredictable results in terms of where the agents will end up in the vasculature are most likely to occur. One approach to better control the behavior of the aggregates of MNP and hence, to better predict the targeted embolization site, is to embed them with the therapeutic load within a single biodegradable matrix. A simple schematic illustrating this concept is depicted in FiguRe 2 with an example of its implementation being shown in FiguRe 3 .
The therapeutic magnetic microcarriers (TMMC) depicted in FiguRe 3 were the first synthesized navigable therapeutic agents [32] . They have been tested in vivo in rabbit models and were designed for the treatment of hepatocellular carcinoma via trans-arterial chemo-embolization after being navigated in the hepatic artery (avoiding the systemic circulations). The TMMC characteristics such as diameter (~50 µm in this particular case) and the drugrelease profile (which was validated experimentally) were similar to drug-eluting beads, which are recognized as promising chemo-embolic systems by inducing tumor anoxia due to physical obstruction and the sustained release of cytotoxic agent such as DOX. Although trans-arterial chemo-embolization differs from systemic injections of therapeutics by being more localized, the addition of navigability of the TMMC is helping to achieve better targeting by influencing the paths of the therapeutics beyond the distal tip of the release catheter.
Drug delivery using a single magnet
Although targeting can be enhanced by an external magnetic field generated by a single 
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future science group magnet placed on the skin as close as possible to the targeted area, the therapeutic outcomes obtained with this approach using magnetic carriers are still generally far from optimal. This is especially true when targeting deeper below the skin. There are two main reasons explaining the suboptimal results of prior magnetic targeting approaches relying on a single magnet. First, because common strategies rely on trapping the magnetic carriers using a statically positioned single magnet instead of relying on more advanced implementations capable of magnetic navigation, these magnetic vectors are still circulating systematically such that a relatively great proportion accumulates in untargeted regions. Second in these approaches, the magnetic field from the external magnet is decreasing exponentially as the distance below the skin increases. Since for a given magnetic material such as iron-oxide, which is intensively used in such target interventions, a very high intensity magnetic field is required to compensate for the very small effective volume of these MNP the efficiency level in magnetic targeting is then restricted to sites very close to the skin below which the magnet is located. Some have suggested to place the magnet inside the body and as close as possible to the tumor. This alternative, although being much more invasive if surgery is involved, does not resolve the fact that systemic circulation is still not eliminated.
Although the single magnet approach has the advantage of being extremely simple to implement in a system point-of-view, navigation of therapeutic agents is not supported and hence, targeting efficacy relies on a relatively small proportion of the therapeutic vectors being trapped at the closest location related to the magnet after systemic circulation. As such, in order to avoid systemic circulation, a magnetic navigation system (MNS) capable of influencing the displacement of magnetic agents between the injection and the targeted sites must be considered.
Single magnet MNS
A single magnet MNS is obviously one of the simplest implementations that can be considered for drug targeting and navigation. A single permanent or electromagnet is typically attached to a robotic arm that moves along a planned path [22] . Initially, these MNS were primarily designed for larger magnetic devices since the MFS decay rapidly from the magnet. Unfortunately, such sharp decay prevents an adequate magnetization for smaller therapeutic agents when operating in deep tissues as the gradients become rapidly ineffective when the distance from the magnet increases.
To increase the MFS in deeper locations, a much stronger magnet becomes mandatory. Indeed, based on previous technological developments for providing MFS in the form a uniform B 0 field in clinical MRI scanners designed for whole body imaging, the MFS obtained with permanent magnets were limited to 0.3 Tesla (T). MFS of 0.4 T were achieved when implemented with water-cooled resistive coils. Today's modern whole-body clinical MRI scanners rely on superconducting magnets that easily exceed 0.4 T with MFS up to 1.5 T and 3 T in clinical settings. These historic facts suggest that superconducting technology is required to go beyond 0.4 T for whole-body interventions. However, superconducting magnets are extremely bulky and as such, they cannot be moved around the patient. Therefore, the obvious practical alternative, when relying on superconductive technology to vary the direction of the magnetic field for navigation purpose, would be to move the patient instead. In a clinical setting, such a platform would typically be designed to move a patient being laid on an extension bed attached to a robotic arm within the relatively strong magnetic fringe field, which emanated outside a clinical MRI scanner from its superconductive magnet. One such approach, known as fringe field navigation (FFN) [23] , can produce six degrees of freedom (DOF) directional gradient fields up to approximately 1.9 T from a 1.5 T scanner (and typically higher with a
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Degrees-of-freedom:
Number of independent motions that can be supported. For drug delivery, 3-degrees-offreedom for translational displacement in all three axes are required while additional degrees-of-freedom, such as rotational movements of the therapeutic carriers, are not required. Reproduced with permission from [23, 32] .
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future science group 3 T scanner) using a sequence similar to the one depicted in FiguRe 4 with a maximum MFS of approximately 0.3-0.5 T (measured from a 1.5 T clinical scanner) at any depths inside a human body. The relatively high but not optimal MFS would increase the magnetization of navigable agents close, or at saturation, for some magnetic materials but not for the ones with the highest levels and especially the ones with a saturation magnetization above 2 T. Nonetheless, from FiguRe 1, it can be observed that the magnetization initially increases rapidly (e.g., slope between point 'b' and point 'c') before slowing down when approaching the saturation point (point 'a' in FiguRe 1) . Hence, such MFS, although not optimal as with magnetic resonance navigation (MRN) (discussed later), can still be generally quite significant in terms of the level of magnetization of the navigable agents. The gradient generated by the rapid decay of the MFS is also extremely high, which compensates significantly for the lower MFS (equation 1) . One major drawback of FFN like any single magnet MNS is the relatively low rate at which the direction of the gradient can be changed, since directional changes are done mechanically by moving either the magnet or the patient. The only practical alternative to increase the directional rate of the magnetic gradient is to use a configuration relying on several electromagnetic coils where electrical currents can be switched and varied more rapidly in order to perform faster electromagnetic actuation (EMA) in all directions as required for effective navigation in more complex vasculatures.
Multimagnet EMA-based MNS MNS technologies are presently aimed and designed for magnetic catheterization procedures. Nonetheless, because relatively high gradients are also generated, such MNS represent state-of-the-art technologies that could potentially be considered for generating the directional fields required for navigating untethered therapeutic agents. The Niobe ® system from Stereotaxis (Mo, USA) is the best-known commercial MNS for catheterization [101] . The platform consists of two computer-controlled permanent magnets positioned and aligned externally to each side of the patient. However, the system lacks the required gradients in the interventional space since the magnet configuration is presently designed to create a relatively uniform magnetic field required for inducing a directional torque on the tip of the instrument that relies on permanent magnets. A MFS of 0.08 T is achieved within an interventional volume of approximately 15 cm in diameter. Beside the fact that the permanent magnets are moved mechanically, the absence of a gradient in the interventional volume prevents the induction of a pulling (displacement) force on therapeutic magnetic agents. Reproduced with permission from [23] .
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Fast directionally changed magnetic gradients can be generated with commercial platforms designed for magnetically-guided catheterization such as the catheter guidance control and imaging system from Magnetecs [102] (CA, USA) and the Cmag catheter steering system from Aeon Scientific [103] (Zurich, Switzerland). Both platforms rely on fixed electrical coils (electromagnets) positioned on both sides of the patient where positional control of the catheter is achieved by varying the ratio of electrical currents circulating in the surrounding coils. Such EMA-based configurations are capable of gradients for wholebody interventions that are limited to less than 0.4 T since superconducting coils are not applicable in such configurations due to the need to support relatively fast switching rates. As a result of the fast decay of the magnetic field from the external EMA-coils surrounding the patient, the MFS is relatively low at approximately 0.14 T and approximately 0.08 T in the interventional space for the catheter guidance control and imaging system and the Cmag system, respectively. Similar gradients and MFS are also the characteristics of other EMAbased MNS systems such as the magnetically guided capsule endoscopy platform that has been jointly developed by Olympus Medical Systems Corporation (Tokyo, Japan) and Siemens Healthcare (Erlangen, Germany) and the experimental EMA system [24, 25] .
n MRN Although adequate when operating permanent magnet-based devices or larger objects based on soft magnetic materials, EMA systems suffer from an adequate MFS in the interventional space to deal with MNP-based agents with overall diameters in the micrometer range. In this respect, it is interesting to note that a 3 T clinical MRI scanner can provide an environment suitable to achieve the highest saturation magnetization of a soft magnetic material by providing a homogeneous or uniform field B 0 = 3 T > 2.43 T. Even a 1.5 T clinical scanner, as widely used in clinics, would bring the magnetization level of MNP closer or at full saturation magnetization depending upon the material being used. This fact can be demonstrated by observing the relationship between the induced magnetic-flux density and the magnetic field, also known as the B-H magnetization curve (FiguRe 1) , that tends to be flattened (horizontal) when approaching the saturation magnetization of such a material, while achieving saturation magnetization for many other magnetic materials (point 'a' in The use of such a MRI environment and in particular, the B 0 field inside the tunnel of the scanner to bring the magnetization at, or closer, to saturation while using superposed directional gradients (such as the ones already implemented in MRI scanners for imaging) to move magnetic cores in a given direction is the fundamental idea of what has been referred to as MRN [26] . Because of the induced directional torque on magnetic therapeutic carriers along the B 0 field, MRN provides only three-DOF (i.e., translational displacements without rotational control of the agents) compared with five or six-DOF for other MNS. Although a high DOF would most likely be required if one is considering using untethered agents for delicate remote surgeries for instance, three-DOF proves to be highly sufficient in drugdelivery application. The lower DOF, due to the use of a high uniform magnetic field in MRN, allows smaller therapeutic agents to be considered and hence, making travel possible in narrower blood vessels for deeper targeting.
MRN uses two fundamental approaches namely, imaging gradient coil (IGC)-MRN or steering gradient coil (SGC)-MRN. With IGC-MRN, the MRI coils are used to generate the directional gradients. With SGC-MRN, dedicated gradients coils are added to the platform. IGC-MRN is capable of fast directional changes (typically 100-200 µs) but with limited duty cycles. SGC-MRN, on the other hand, has unlimited duty cycles but with slower directional changes (typically few tens of ms).
Three fundamental MRN implementations can be considered. The first one referred to as MRN-software (SW), relies on upgrading a clinical MRI scanner with MRN-enabling software only (i.e., without hardware modifications to the scanner). The first in vivo demonstration of MRN-SW was done in the carotid artery of a living pig where a 1.5 mm chromesteel bead was navigated automatically following preprogrammed waypoints at an average velocity of 10 cm/s [27] .
MRN-SW is somewhat limited by the fact that the magnetic gradients used for wholebody scans are relatively low (typically 40 mT/m) to allow MRN to be effectively done on magnetic therapeutic agents synthesized The second configuration simply upgrades the scanner by installing an additional coil assembly. Such coil assembly allows much higher gradients (typically more than 300 mT/m) inside the tunnel of a clinical scanner. This particular configuration known as MRN-upgraded (MRN-U) can be done with a high gradient imaging coil insert (MRN-UI) implementing IGC-MRN, dedicated propulsion or steering coil inserts (MRN-US) implementing SGC-MRN, or with a double insert containing both imaging and steering coils [28] . An example of a MRN-U double insert containing both imaging and steering coils is depicted in FiguRe 5 .
The main advantage of MRN-US is the possibility to generate high sustained gradients for a prolonged period, which is not the case for MRN-UI where the imaging coils may overheat after a period of operation (typically a few minutes) before interrupting the intervention to allow for cooling. But unlike MRN-UI, the slew rate for MRN-US is relatively low with a rise time of a few tens of ms for 0-300 mT/m. Such a rise time limits the rate of directional changes of the gradients in the vasculature for navigation purpose. MRN-US can navigate TMMC down to approximately 50 µm in diameter as depicted in FiguRe 2 , where such TMMC were navigated through the hepatic artery to target specific lobes of the liver in rabbit models [29] .
MRI-UI allows the generation of much higher slew rates with rise time in the order of 100 µs for 0-300 mT/m. By decreasing the inner diameter of the coils assembly, the peak gradient can be increased further. For instance, an imaging gradient coil insert with a peak gradient of 600 mT/m and a maximum slew rate of 3200 T/m/s (5 ms rise time) have been implemented [30] . Such systems relied on an insert with an inner diameter of 32 cm which operated at the maximum amplitude of 500 mT/m with a slew rate of 1800 mT/m/ms in order to minimize vibration and acoustic problems.
MRN-U generates gradients that are not only equivalent or superior to the most powerful MNS but the much higher magnetization level of the magnetic material, achieved by generating a much higher MFS in the interventional space, results in superior induced force on soft magnetic cores including MNPbased therapeutic agents. However, MRN-U is limited by its applicability by the lower inner diameter of the additional coil assembly that prevents whole-body interventions to be performed. Such smaller inner diameter restricts MRN to smaller diameter parts of the body such as the limbs or the head.
The third MRN configuration is based on a clinical MRI scanner capable of higher gradients (also known as ultra-high gradients scanners) capable of supporting whole-body MRN. This configuration, referred to here as MRNwhole-body (or simply MRN-WB), is typically characterized with reduced MRI linearity. One example of such platform capable of being converted to MRN-WB has been described in [31] . The platform can generate maximum gradients of 300 mT/m with a slew rate of 200 T/m/s allowing also for time-multiplexed MR-tracking was achieved with an inner diameter appropriate for whole-body interventions. A MAGNETOM Skyra 3T magnet (Siemens, Erlangen, Germany)was modified in order to achieve a slew rate of >200 T/m/s. To achieve such specifications, each of the three orthogonal axes x, y, z was split into four independently driven segments. As in the case of MRN-UI, MRN-WB suffers from restrictions of the Reproduced with permission from [23] .
A u t h o r P r o o f
future science group duty cycle, which becomes relatively small for sustained operations. This duty cycle can be increased when operating in burst mode but by doing so, the total operating time between successive cooling phases has to be considered in the medical interventional protocol. This type of platforms is also relatively much more expensive compared with traditional scanners and it is currently not widely available.
Tracking & imaging of theranostic agents
Magnetic therapeutic agents have the advantage of being visible using MRI since the same MNP used to induce a propelling force can also serve as MRI contrast agents. As a result of being defined as theranostic agents, they can be tracked between the injection site and the final target and an image of these agents can be gathered to assess targeting efficacy. The real-time tracking of such theranostic agents is critical when closed-loop navigation control is used.
Closed-loop control provides corrective actions in the form of adjusted magnetic gradients to maintain the navigable agents along a planned trajectory. Faster is the feedback loop in such a scheme and faster the system can react to external perturbations that can deviate the agents from the planned target. EMAbased MNS typically use x-ray technology to gather the positional information of the agents instead of MRI during MRN. x-ray is known to be faster than MRI and as such, EMA-based MNS would typically have an advantage in a closed-loop navigation sequence. However, there are advantages in MRI that may favor MRN in navigation control of theranostic agents if certain complementary approaches are considered [23] .
Indeed, MRN has the advantage of being able to induce more propelling force on smaller theranostic agents but by doing so, it must rely on MRI technology to gather positional information inside the vasculature (see FiguRe 6 for some examples). Although MRI is a relatively slow process compared with x-ray, it can detect agents that are smaller than the spatial resolution of the MRI scanner and agents that would be impossible to detect using other medical imaging modalities including x-ray. This is possible by synthesizing the agents to create a field inhomogeneity in the MRI scanner that is larger than the size of a single voxel. But the capability of sensing such small agents is a trade-off for a longer-image acquisition time. Instead of gathering the whole image, MR-tracking of the agent alone can be done using an algorithm such as magnetic signature selective excitation tracking [32] . Although the real-time tracking performance can be improved depending on the magnitude of the MR-image artifacts, registration process on a pre-acquired image of the vasculature and tissues can introduce additional positional errors. Another drawback of MRN is that MRI or tracking and MR-propulsion cannot be done at the same time due to the generation of propulsion gradients that would interfere with the MRI sequences. Compensation methods to perform MRN control as described in reference [23] include; predictive algorithms; the use of modulated flow control, where the blood f low is modulated and synchronized with the MRN control cycles; successive targeted embolization sequences, where temporary targeted embolizations are performed by special navigable embolization agents at selected blood vessel entrances to prevent the therapeutic agents escaping the planned path; and the scout method using MRN sequences consisting of several directional gradients of predetermined magnitudes, directions, and time of activation that are adjusted based on the previous assessment of the targeting efficacy. Although MRN-WB seems to be the best approach, it is expensive, not widely available and cooling cycles are required since the coils tend to overheat during MRN. Unlike for a single-magnet MRN approach and EMA-based MNS, which typically use x-ray as an imaging or tracking modality that can be used at any time, MRN must use MRI sequences that are 
Comparison of the various MNS approaches
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Beyond the arterioles
Although the idea of propelling and steering such navigable therapeutic agents towards a target can be attractive, there are technical constraints that must be taken into account. The main challenge is to first provide sufficient propelling directional force to each navigable agent. This is not obvious considering the constraint imposed by the overall size of each agent, which cannot exceed just a few µm across (ideally no more than ~2 µm) to allow successful transits through the angiogenesis network while offering the maximum volume or surface to attach the therapeutic payloads. All MNS, including MRN relying on magnetic induction of forces are, not capable of navigating agents with dimensions appropriate to reach tumoral regions when operating in deep tissues. In the best cases, a few tens of µm in diameter agents capable of transiting in the arterioles can be supported. Since no other methods relying on induction from an external source are available, self-propelled therapeutic agents must be considered for transiting in narrower capillary vessels including the angiogenesis network. Reproduced with permission from [23] .
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Assuming successful optimal transits through the angiogenesis network, such agents would then enter the tumor interstitial fluid microenvironments made of the hypoxic and the necrotic regions. The highly elevated tumour interstitial fluid pressure TIFP increases resistance to interstitial fluid flow and most often prevents adequate diffusion of conventional (without propelling force) therapeutic agents. Hence, agents with propelling capability would become a real asset compared to conventional agents in such microenvironments. Although the TIFP is relatively constant inside the interstitial microenvironments (except when closer to the boundary with the angiogenesis network), the pressure gradient on the other hand can reach levels ranging typically from 10 to 40 mmHg (1 mmHg = 133.322, Pa = 1.33 × 10 -10 N µm -2 ) against human tumor walls [33] [34] [35] . Such high pressure gradients make the injection of micrometer-sized agents through a perforation of the tumor extremely challenging and not practical or suitable in most cases. This fact suggests that indeed, entering the tumor through the angiogenesis network would be a far more suitable approach.
Assuming proper displacements of these agents in the interstitial fluid microenvironments, the next challenge would be to move towards the hypoxic regions that can be distributed at different locations inside the tumor. Such heterogeneity with hypoxic regions not visible with sufficient spatial resolution using any existing medical imaging modalities alone makes the task of effective targeting the hypoxic regions even more challenging. However, since the oxygen content in the interstitial fluid is decreasing gradually from the end of the angiogenesis network next to the hypoxic zones to zero in the necrotic regions passed the hypoxic microenvironments, suggests that an O 2 sensor embedded in each navigable agent would be a suitable addition. However, to be effective, an O 2 sensor capable of detecting such oxygen gradient should not only be embedded in each navigable agent, but the sensory information should also be able to influence its directional displacement. This means that the propelling system should also be embedded in such navigable agent, otherwise, a duplex communication link would have to be established between the agents and an external computer responsible to control the induction of the propelling force from an external source. Since the latter solution may prove to be technologically much more challenging, the first option appears to be the best approach in this respect. To be most effective in a therapeutic point-of-view, a specific lowoxygen threshold corresponding to the oxygen level found in the hypoxic regions should be set within such navigable agent as an indicator that the targeted area has been reached in order to release the therapeutics at the right optimal locations.
Magnetotactic bacterial therapeutic agents
One practical strategy to implement such highly functional therapeutic agents, considering current technological constraints, is to harness microorganisms that offer the required functionalities and characteristics for such types of therapeutic delivery. Towards this trend, bacteria are potential alternatives for the implementation of these therapeutic agents due mainly to their adequate dimensions to transit the angiogenesis network [36] , their selfpowered capability (without requirement for inductive power, which is known to be a real technical constraint at such a scale), their flagellated propulsion systems, which have proven to be very effective in low Reynolds hydrodynamic conditions, as encountered in the tumor microenvironments, and for some species, their ability to seek low oxygen concentrations.
Indeed, nonpathogenic, anaerobic bacteria that preferentially localize and proliferate in the hypoxic regions of tumors have been investigated as cancer treatments with mixed success [37] . To increase the therapeutic outcomes, these bacteria have been investigated later as delivery vehicles of conventional drugs, a strategy 
Key Terms
Magnetotaxis: Describes the ability to sense a magnetic field and to coordinate its directional displacement in response.
Microaerophilic behavior:
Seeking low oxygen concentration. The microaerophilic behavior of some microorganisms, especially some species of bacteria, can be exploited to deliver therapeutics in hypoxic regions of solid tumors.
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future science group referred to as combination bacteriolytic therapy. Besides the need to have bacteria without toxic genes, a major issue is the necessary high dose required to induce a significant therapeutic effect, which most of the time is associated to severe systemic toxicities [38] .
Although combining bacterial therapy with other conventional methods such as chemotherapy or radiotherapy by carrying the required therapeutic cargo appears to be mandatory in most cases for complete tumor consumption, bacterial attraction to the tumor close enough to allow the detection of oxygen gradients must be supported. To this end, external assistance is required to guide these bacteria at the hypoxic-angiogenic transition where oxygen gradients are present and can be detected.
One suitable directional means that is not influenced by variations in tissue density and that can be generated at any depth in the human body by an external platform based on the location of the tumor gathered from a medical imaging modality (or other means), is the use of a directional magnetic field. As such, magnetotactic bacteria (MTB) were investigated to fulfill the role of therapeutic agents to achieve more effective targeting of solid tumors [39, 40] . MTB are flagellated cells that synthesize a chain of intracellular-enveloped single-magnetic domain nanoparticles known as magnetosomes [41, 42] . Such chains acts as a miniature compass needle which, when a directional torque is induced from a relatively weak magnetic field, can serve as an embedded steering system to influence the directional motions of the MTB.
In particular, MTB of strain MC-1 have been of special interest for several reasons [40] . First, the bacterial cell is round with a diameter between 1 and 2 µm, making it ideal to transit in the narrowest capillaries found in humans, including the angiogenesis network, while being adequate to transit through the cellular malformations in the interstitial fluid microenvironments of solid tumors. This overall size also provides the optimal surface to attach the maximum therapeutic payload. Second, the thrust force provided by two bundles of flagella entails the MTB to swim at an average velocity of approximately 200 µm s -1 with peak velocities reaching approximately 300 µm s -1 (measured experimentally in PBS at room temperature). These values represent approximately ten-times the velocities of many other known flagellated bacteria. Third, it is polar meaning that unlike axial MTB, the cell swims persistently in one direction, either towards an artificial North pole (North seeking) located at the region to be treated and generated for tumor targeting by a special platform referred to as the magnetotaxis system (FiguRe 7) , or towards an artificial South pole (South seeking). For polar MTB, the direction of the cells (North or South seeking) can be preprogrammed or preselected prior to the injection, that is not the case for axial MTB which will swim along the magnetic field lines in either direction. Fourth, initial analysis suggests that the MC-1 cells do not carry toxic genes and preliminary tests performed in mice, including cytotoxicity and immune system responses, show that they are potential candidates for drug-delivery applications. Fifth, this species of bacteria has been successfully cultivated in the laboratory with highly repetitive and reliable propelling and magnetotactic behaviors making it a serious candidate for the production of bacterial-based therapeutics with highly predictable behaviors for control and targeting purposes. Finally, the response of the MC-1 microaerophilic bacteria forces them to migrate towards approximately 0.5% oxygen level, which generally corresponds to the oxygen level expected at the hypoxic regions of solid tumors.
Artificial micro-swimmers
Various miniaturized helical micro-swimmers including artificial bacterial f lagella (ABF) configurations, such as the one depicted in FiguRe 8 , have been investigated as potential drug micro-carriers. ABF exploits the torque generated by a directional rotating magnetic field to move in a given direction. Although the magnetic field necessary for propulsion is far less than the ones used in gradient-based systems such as MRN platforms, the resulting velocities are far inferior to the ones achieved by the MC-1 MTB. The maximum velocity that was recorded was for a 38 µm in length ABF. The measured velocity of 18 µm s -1 using a rotating magnetic field of 2.0 mT (maximum thrust (pushing) force of 3 pico-Newtons [pN]) corresponding to approximately half a body length per second is far from the propelling efficiency of the MC-1 bacteria achieving approximately 100 and 150 cell lengths per second for the average and peak velocities, respectively [46] . The structure of the ABF could be optimized
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future science group to achieve superior velocities. For instance, a recent study showed that the velocity of this particular ABF could be increased to 170% of its original value [47] , which is still modest compared to the MC-1 cell. Although the ABF velocity profile is constant and is not characterized by a decay, as for the MC-1 MTB, the relatively low velocity of ABF remains a critical issue especially immediately after the injection in the peritumoral regions where presently the higher velocities of the MC-1 cells will mostly lead to higher targeting efficacy while reducing systemic circulation compared with actually known miniaturized artificial-helical micro-swimmers.
Conclusion
In cancer therapy, systemic circulation of toxic agents throughout the vascular network remains often the only option. Such an approach often leads to increased toxicity to healthy organs and tissues while delivering relatively low dose of therapeutic in the vicinity of the regions to be treated. In this respect, direct targeting using appropriate platforms and navigable therapeutic agents can help enhancing targeting and therapeutic efficacy while minimizing systemic circulation. However, such a complementary approach is only applicable when the targeted region to be treated is localized and has been identified. The range of applicability includes solid tumors and the delivery to other localized regions in the body that need therapeutics or agents capable of diagnostics or imaging such as navigable contrast agents. Although direct targeting with navigable agents has the potential to significantly enhance the therapeutic index and outcomes of the most deadly localized cancers, it is of no use for nonlocalized cancers such as bones, skin melanoma and blood-related cancers.
Direct targeting using navigable agents is also a very new area of research when we consider that the first demonstration of navigating an untethered object in the artery of a live animal was done in 2006 with the results being published in 2007 [30] . Since then, very few demonstrations with therapeutics in animal models have been successfully conducted. However, the field is progressing fast. Although approximately two main research groups worldwide are presently developing platforms and techniques specially designed for navigating agents for drug delivery, several other research groups are contributing in developing or enhancing techniques and algorithms that could be implemented in such Then an artificial magnetic pole located at the targeted site (left) and generated by a special platform known as the magnetotaxis system entails the drug-loaded bacteria to migrate and aggregate (bottomright) within a zone referred to as the aggregation zone. Within the aggregation zone, the bacteria are influenced by their microaerophilic behaviors since the magnetic field strength becomes too weak for magnetotaxis directional control. Reproduced with permission from NanoRobotics Laboratory, Polytechnique Montréal.
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future science group platforms. The low number of research groups involved in developing such platforms can be partly explained by the fact that this area of research is highly complex to manage due to the high interdisciplinary nature of the projects involved. In such an endeavor, engineers and scientist are working in close collaboration with several experts in areas such as biochemistry, oncology, material sciences, and biology, to name just a few. Nonetheless, the field is progressing fast with more tangible results on the horizon. While the increased interest from the medical and the pharmaceutical industries are other signs of the potential of this new approach in cancer therapy.
Future perspective
Engineering principles are just beginning to be integrated into drug delivery applications for cancer therapies. To date, only a few experiments have been conducted in animal models only. These include the delivery of DOX using TMMC to specific regions in the liver of rabbits after navigation in the hepatic artery, the delivery of drug using MC-1 magnetotactic bacteria in hypoxic regions of xenografts in mice, and the injections in specific points of drug in pig's eyes using EMA-based platform. Although in its infancy, several mature principles that have proven to be effective in other applications are being considered and adjusted to be integrated in platforms and therapeutic agents to enhance targeting efficacy further. Such complementary techniques will most likely influence not only the synthesis of some therapeutic agents but also the methods used for fighting as well as performing diagnostics for localized cancers. Such engineering principles will become highly interdisciplinary in order to further enhance the effectiveness of such new therapeutic approaches. For example, although MTB-based therapeutic agents perform very well in low Reynolds hydrodynamic conditions as encountered in micro-vessels and in the tumor microenvironments, their motility when exposed to physiological conditions immediately after injection decreases to zero over a period of approximately 40 min. Although from preliminary experimental results conducted in animal models, such a time appears to be ample to target solid tumor when peritumoral injection is performed, it precludes injections further away from the target site. Furthermore, MTB are inefficient in larger vessels where the blood flow is more significant. As such, drug-loaded MTB must be encased with MNP in EMA-based transporters such as MRN-compatible micro-carriers if peritumoral (or near the target) injection is not an option. Another potential prospect is the exploitation of the same MNP used for inducing a propelling force and acting as a MRI contrast agent for tracking purposes, to induce hyperthermia using a modulated magnetic field. The same principle can also be used to temporarily open the blood-brain-barrier for the delivery of drug molecules for brain tumors and diseases. Those are just a few examples of future developments coming from the applications of principles of physics to help achieve better targeting in cancer therapies.
Although still in its infancy, direct targeting is progressing at a very fast pace and several types of navigable agents are already under investigation. By combining the expertise acquired for passive and active targeting, direct targeting could potentially offer new tools for the delivery of therapeutics. 
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